Singapore focuses its life science strategy on humans  by Lee, Kenneth
Over the last decade, the tiny island
republic of Singapore — with a
population of 3 million and no
natural resources — has invested
more than US$3.5 billion to make
life sciences one of the pillars of its
new economy. Whereas the
government once embraced all areas
of life sciences, and only a few years
ago was talking of developing
Singapore into an agrobiology hub
for the Asia Pacific region, the focus
today is firmly on humans and not
animals or plants.
Speaking at a recent life science
investment seminar held in
Singapore, Philip Yeo, who is head of
Singapore’s Economic Development
Board and the man responsible for
shaping the country’s life science
strategy, said that the priority would
now be on “looking for drugs, for
example, a cure for cancer, and ways
to treat people”. He added that the
term ‘human life sciences’ would be
more appropriate to the Singapore
context. 
The change in Singapore’s
priorities coincides with, but does
not seem to be prompted by, the
trend for life science companies such
as Novartis and AstraZeneca to shed
their agricultural interests and
concentrate on the more profitable,
and less controversial, business of
pharmaceuticals. Asked to explain
the change in tack, Philip Yeo,
explained: “There’s no agriculture in
Singapore. Why do I want to waste
my time on agriculture when there
are human beings to take care of?”
Mr Yeo, who is said to spend his
spare time reading up on genes and
chromosomes when other men his
age are playing golf, is quoted in a
local tabloid as saying “we are
interested in those that can walk, not
in things with roots.”
The Singapore government takes
its advice from an international
committee of industry leaders and
scientists headed by Sir Richard
Sykes, non-executive chairman of
Glaxo SmithKline, and Sydney
Brenner, president of the Molecular
Sciences Institute in San Diego.
At the investment seminar, the
government announced a
US$15 million business-plan
competition for proposals to create
new start-ups in four
areas — pharmaceuticals,
biotechnology, medical devices and
healthcare services. 
`We are interested in those that
can walk, not things with roots’
The seminar, ironically, was
hosted by Singapore’s Institute of
Molecular Agrobiology (IMA), which
was established in 1995 with
government funding and only
recently moved into a new building.
Mr Yeo would not comment directly
on the future of the IMA, and while
no one believes that the
IMA — which has close ties with
industry — is about to fold up, his
comments suggested that the
institute might be weaned from
government funding.
The seed money for new start-
ups comes from a US$600 million life
science investment fund set up by
the government last year. A further
US$600 million is available to fund
what the Economic Development
Board calls public R&D, for instance,
the Singapore genomics programme
established in June last year. The
programme, which will take
advantage of Singapore’s stable racial
mix of Chinese, Malays and Indians,
aims to target diseases that are
prevalent in the region. 
A third US$600 million will be
used to tempt world-class
pharmaceutical companies into
setting up R&D bases in Singapore.
The government hopes that its
investment will help biotechnology
in Singapore to outgrow its academic
roots and become a key industry.
Already, Aventis, Glaxo SmithKline,
Merck and Schering Plough have
established manufacturing plants in
Singapore.
Singapore’s life science ambitions
kicked off in 1987 with the
establishment of an Institute of
Molecular and Cell Biology (see Curr
Biol 8:R72). In the short space of a
decade, the institute’s scientists have
garnered an impressive number of
publications in high-profile journals,
helping put Singapore on the map as
a centre for high-class biomedical
research.  But about 80% of the
institute’s 30 research groups are still
headed by foreigners, many of whom
are Chinese nationals who trained in
the West. 
It is not lost on the Singapore
government — whose skill at micro-
managing the country is
renowned — that it has to train a
whole spectrum of talent, not only
researchers, but also people with a
head for business. To this end, it has
budgeted US$35 million for life
science scholarships over the next
five years. And last month, plans
were unveiled for a College of Life
Sciences to be built at a cost of over
US$270 million, with almost
US$30 million a year available for
salaries and operating expenses. The
college will offer an interdisciplinary
BSc programme that combines
biology with information technology,
engineering and physics, with
modules in business and
management.
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